特发性矮身材中西医治疗进展

doi:10.20274/j.cnki.issn.1674-3865.2025.06.007

摘要/Abstract

摘要：

特发性矮身材是一组病因未明、高度异质的矮小疾病的统称，是造成儿童矮身材的主要原因。若未及时干预，容易引发患儿心理障碍及社会适应困难，严重影响其终身发展质量。目前，西医治疗以重组人生长激素替代疗法为核心方案，同时辅以促性腺激素释放激素类似物、芳香化酶抑制剂等调节性发育进程的药物。中医则通过辨证施治体系，运用中药内服、针灸推拿及穴位贴敷等外治疗法，在促进骨骼生长，调节内分泌代谢及改善体质方面展现出独特疗效与机制优势。

关键词: 特发性矮身材, 中医治疗, 西医治疗, 儿童

Abstract:

Idiopathic short stature is a collective term for a group of highly heterogeneous conditions with unknown causes, primarily responsible for the short stature in children. If not promptly addressed, it can easily lead to psychological disorders and social adaptation difficulties in patients, significantly impacting their lifelong development quality. Currently, in western medicine, the core treatment approach is recombinant human growth hormone replacement therapy, supplemented by drugs that regulate the developmental process, such as gonadotropin-releasing hormone analogs and aromatase inhibitors. In traditional Chinese medicine, a syndrome-differentiated treatment system is employed, and internal administration of herbal medicines combined with external therapies of acupuncture, massage, and topical application of patches is used to promote bone growth, regulate endocrine metabolism, and improve physical condition, which demonstrates unique therapeutic effects and mechanism advantages.

Key words: Idiopathic short stature, Traditional Chinese medicine and western medicine treatment, Child

中图分类号:

R339.3+5

任若云, 杨文庆. 特发性矮身材中西医治疗进展[J]. 中国中西医结合儿科学, 2025, 17(6): 498-502.

Ruoyun REN, Wenqing YANG. Progress in traditional Chinese and western medicine treatments for idiopathic short stature[J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(6): 498-502.

参考文献 43

[1]	陈佳佳, 曹冰燕, 巩纯秀, 等. 儿童特发性矮身材诊断与治疗中国专家共识[J]. 中国实用儿科杂志, 2023, 38(11): 801-813.
[2]	Backeljauw P, Cappa M, Kiess W, et al. Impact of short stature on quality of life: a systematic literature review[J]. Growth Horm IGF Res, 2021, 57-58: 101392.
[3]	陈瑞敏, 艾转转, 蔡彬彬. 生长激素治疗儿童特发性矮身材的研究进展[J]. 中国实用儿科杂志, 2023, 38(11): 838-842.
[4]	Yang L, Yang F. Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis[J]. BMC Pediatr, 2025, 25(1): 28.
[5]	Maghnie M, Ranke MB, Geffner ME, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort[J]. J Clin Endocrinol Metab, 2022, 107(12): 3287-3301.
[6]	Wu D, Chen RM, Chen SK, et al. Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty[J]. BMC Pediatr, 2020, 20(1): 138.
[7]	Yuan J, Fu J, Wei H, et al. A randomized controlled phase 3 study on the efficacy and safety of recombinant human growth hormone in children with idiopathic short stature[J]. Front Endocrinol (Lausanne), 2022, 13: 864908.
[8]	张东光, 杨玉, 杨利, 等. 重组人生长激素治疗特发性矮小患儿的临床研究[J]. 中国临床药理学杂志, 2025, 41(2): 169-173.
[9]	Zhu J, Yuan K, Rana S, et al. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis[J]. Sci Rep, 2024, 14(1): 8061.
[10]	Rodaro C, Tamaro G, Faleschini E, et al. Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency[J]. Ann Pediatr Endocrinol Metab, 2025, 30(2): 106-110.
[11]	Albers N, Cadarette S, Feakins B, et al. Long-acting growth hormone for pediatric growth hormone deficiency[J]. J Endocr Soc, 2025, 9(5): bvaf040.
[12]	Kang E, Chung LY, Rhie YJ, et al. Long-term effectiveness and safety of long-acting growth hormone preparation in children with growth hormone deficiency[J]. J Pediatr Endocrinol Metab, 2024, 37(12): 1036-1046.
[13]	Iughetti L, Insalaco A, Predieri B, et al. Long-acting growth hormone in the treatment of children with growth hormone deficiency[J]. Expert Rev Endocrinol Metab, 2025, 20(3): 169-186.
[14]	Luo X, Zhao S, Yang Y, et al. Long-acting PEGylated growth hormone in children with idiopathic short stature[J]. Eur J Endocrinol, 2022, 187(5): 709-718.
[15]	Xie L, Li Y, Zhang J, et al. Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study[J]. Eur J Pediatr, 2024, 183(10): 4531-4539.
[16]	聂晶, 孟仙, 吴晓玲, 等. 不同剂型重组人生长激素对特发性矮小症的疗效分析[J]. 中国现代应用药学, 2023, 40(22): 3136-3140.
[17]	张德会, 程文旭, 张伦敏, 等. 长效与短效重组人生长激素治疗特发性矮小症患儿的临床研究[J]. 中国临床药理学杂志, 2024, 40(15): 2178-2181.
[18]	Khawaja N, Owaineh H, Batieha A, et al. The effect of gonadotropin-releasing hormone analogue on final adult height in children with idiopathic short stature[J]. Med Princ Pract, 2019, 28(6): 509-516.
[19]	Li Y, Du M, Ma H, et al. Efficacy of letrozole in treatment of male adolescents with idiopathic short stature[J]. J Zhejiang Univ Med Sci, 2020, 49(3): 308-314.
[20]	Wang S, Wu Z, Chen Y, et al. Comparative efficacy of aromatase inhibitors and gonadotropin-releasing hormone analogue in increasing final height of idiopathic short stature boys: a network meta-analysis[J]. Front Endocrinol (Lausanne), 2023, 14: 1167351.
[21]	Wang W, Wang Y, Xiao Y, et al. Effects of different therapy regimens to increase final adult height in males at advanced bone age with idiopathic short stature[J]. BMC Pediatr, 2023, 23(1): 615.
[22]	王华姨, 高莉莉, 赵彤, 等. 单用rhGH、GnRHa及联合应用对青春期早发育特发性矮身材患儿的疗效观察[J]. 徐州医科大学学报, 2020, 40(9): 699-702.
[23]	陈晓梅, 刘佳佳, 邱佳静, 等. rhGH单独或联合GnRHa治疗青春期特发性身材矮小症男童的效果比较[J]. 中国民康医学, 2022, 34(6): 146-148.
[24]	Zegarra W, Ranadive S, Toulan D, et al. Anastrozole vs letrozole to augment height in pubertal males with idiopathic short stature: a 3-year randomized trial[J]. J Endocr Soc, 2024, 8(10): bvae141.
[25]	李燕虹, 杜敏联, 马华梅, 等. 来曲唑改善青春期特发性身材矮小症男性患儿成年身高的疗效评价[J]. 浙江大学学报(医学版), 2020, 49(3): 308-314.
[26]	张旭. 阿那曲唑联合重组人生长激素治疗青春期特发性矮身材男童的临床研究[D]. 合肥: 安徽医科大学, 2023.
[27]	周桂藏. 芳香化酶抑制剂联合基因重组人生长激素治疗大骨龄矮身材男童的疗效观察[D]. 青岛: 青岛大学, 2020.
[28]	夏萌萌, 向金波, 罗军, 等. 芳香化酶抑制剂在改善儿童身材矮小症中的作用[J]. 中国药房, 2025, 36(4): 501-506.
[29]	中国老年保健协会生长发育和性腺疾病分会,中国医师协会青春期医学与健康专业委员会. 芳香化酶抑制剂改善青少年身高的临床应用专家共识[J]. 中华医学杂志,2024,104(32):3010-3018.
[30]	王亚宁, 杜春雁. 近5年中医药治疗儿童特发性矮小症研究进展[J]. 中医儿科杂志, 2025, 21(2): 96-100.
[31]	许翰, 潘曌曌. 中医治疗特发性矮小症临床研究进展[J]. 甘肃中医药大学学报, 2025, 42(3): 80-86.
[32]	彭田芳, 易小莲, 林艳, 等. 健脾助长方治疗脾虚型特发性矮小症临床研究[J]. 浙江中西医结合杂志, 2024, 34(11): 1006-1009.
[33]	潘丹萍, 韩雪, 孙凤平. 补中助长颗粒联合生活方式干预脾虚型特发性矮身材疗效观察[J]. 西部中医药, 2022, 35(3): 96-99.
[34]	张庆玲. 参胡助长汤治疗脾虚肝旺型特发性矮小症的临床观察及作用机制探索[D]. 哈尔滨: 黑龙江中医药大学, 2023.
[35]	王亚宁. 特发性矮小症中医证候分布规律与健脾益肾推拿技术治疗其脾肾阳虚证的临床研究[D]. 天津: 天津中医药大学, 2024.
[36]	周红, 韩光玺, 崔芬芬, 等. 春季助长贴联合耳穴贴压治疗特发性矮身材脾肾两虚证40例临床观察[J]. 中医儿科杂志, 2024, 20(2): 86-90.
[37]	吴佳妮, 徐群明, 王敏华, 等. 醒脾滋肾法在学龄期特发性矮小症中的应用[J]. 辽宁中医杂志, 2025, 52(1): 63-66.
[38]	严伟, 丁苗苗, 宋锦萍. 基于扶阳理论探析针灸干预儿童脾肾两虚型特发性矮小症的临床研究[J]. 南京中医药大学学报, 2023, 39(6): 575-579.
[39]	李红玉, 叶进. 小儿助长方加减联合重组人生长激素治疗小儿特发性矮小症脾肾两虚证的效果及安全性[J]. 临床合理用药, 2024, 17(33): 23-27.
[40]	王雪峰, 张秀英. 儿童矮身材的中医认识及辨证施治[J]. 中国中西医结合儿科学, 2024, 16(5): 380-383.
[41]	Li L, Chen L, Yang Y, et al. Characteristics of gut microbiome and its metabolites, short-chain fatty acids, in children with idiopathic short stature[J]. Front Endocrinol (Lausanne), 2022, 13: 890200.
[42]	Yan L, Ye B, Yang M, et al. Gut microbiota and metabolic changes in children with idiopathic short stature[J]. BMC Pediatr, 2024, 24(1): 468.
[43]	Yuan J, Wang Y, Huang Y, et al. Investigating novel therapeutic approaches for idiopathic short stature: targeting siRNA and growth hormone delivery to the growth plate using exosome nanoparticles[J]. Adv Sci (Weinh), 2024, 11(24): e2309559.